Get started
Ocugen, Inc.Ocugen, Inc.Ocugen, Inc.

Ocugen, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

OCGN trade ideas

$OCGN is gonna fall todayPupm&Dump trading strategy idea. $OCGN is rising without clear preconditions today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $0,449; stop-loss — $0,512; take-profit — $0,323; Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:OCGNShort
by KozakHlib
21
Fourth FDA Orphan Drug Designation for OCU400 (AAV-NR2E3)Ocugen Receives Fourth FDA Orphan Drug Designation for the Same Product, OCU400 (AAV-NR2E3) Gene Therapy, for the Treatment of Another Key Inherited Retinal Disease (IRD), PDE6B Gene Mutation-Associated Retinal Diseases The FDA Office of Orphan Products Development grants orphan designation for novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. Orphan designation qualifies the sponsor of the drug for various development incentives of the Orphan Drug Act, including a seven-year period of U.S. marketing exclusivity, tax credits for clinical research costs, clinical research trial design assistance, the ability to apply for annual grant funding and waiver of Prescription Drug User Fee Act filing fees. finance.yahoo.com
NASDAQ:OCGN
by AlenCiken
2
Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Ocugen Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Disease Third orphan drug designation for the same product finance.yahoo.com TWITTER It seems they received a Notice of Allowance for ANOTHER U.S. patent and just paid their fee last week. I assume we will hear about this too in addition to their latest orphan drug status designation? They have a lot of good news. A bit of insider purchases in May too. I assume they will announce both soon. Typically no pr is made until the notice of issue is granted with the patent number & grant date. This happens shortly after the notice of allowance is granted and the fee is received (& other minor administrative items are completed). It has not even started clinical trials yet! Face with tears of joy Lol!! orphan drug status means the costs to test and develop will be substantially subsidized by the government for public policy reasons. So this is basically an announcement that they received a free $150M. According to the FDA website, $OCGN just received orphan drug status to complete its OCU400 modifier gene therapy platform! I have not seen any PR yet. They will also present at the World Orphan Drug Congress next month.
NASDAQ:OCGN
by AlenCiken
2
OCUGEN MAJOR BULL RUN INCOMING!Hey guys! A lot of you may not know this but I actually do some stock trading on the side as well as creating YouTube videos. Recently I came across this stock and honestly in my past 5 years of trading I have never come across something that looks more of an attractive buy than this stock...OCUGEN! And I'm going to explain why for a number of reasons. 1) We can see a clear elliot wave 1 & 2 being completed with a 0.618 retracement on the fibonacci 2) As the retracement was heavy for wave 2, we can expect the retracement for wave 4 to be less and indeed we do see this as wave 3 hits a peak and wave 4 retraces to the 0.382 3) Wave 5 is sure to be a fruitful wave! Take a look at everything from the RSI showing an amazing trend line on the 30 minute & histogram now ticking to the positive on the hourly 4) Lastly...switch over to monthly. THERE HASN'T BEEN VOLUME LIKE THIS IN MONTHS! Definitely bullish and I'll be keeping an eye out for a breakout past the triangle. Happy trading!
NASDAQ:OCGNLong
by SMASHBengali
2